Personalis/$PSNL
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Personalis
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. The company' products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.
- Ticker
- $PSNL
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 260
- Headquarters
- Fremont, United States
- Website
- www.personalis.com
Personalis Metrics
BasicAdvanced
$1.7B
-
-$1.10
2.28
-
Price and volume
Market cap
$1.7B
Beta
2.28
52-week high
$18.89
52-week low
$4.96
Average daily volume
2.3M
Financial strength
Current ratio
5.283
Quick ratio
4.91
Long term debt to equity
0.128
Total debt to equity
0.162
Interest coverage (TTM)
-536.66%
Profitability
EBITDA (TTM)
-104.596
Gross margin (TTM)
12.69%
Net profit margin (TTM)
-153.84%
Operating margin (TTM)
-164.07%
Effective tax rate (TTM)
-0.03%
Revenue per employee (TTM)
$270,000
Management effectiveness
Return on assets (TTM)
-25.03%
Return on equity (TTM)
-50.32%
Valuation
Price to revenue (TTM)
21.935
Price to book
7.08
Price to tangible book (TTM)
7.08
Price to free cash flow (TTM)
-15.135
Free cash flow yield (TTM)
-6.61%
Free cash flow per share (TTM)
-1.034
Growth
Revenue change (TTM)
-13.26%
Earnings per share change (TTM)
-6.88%
3-year revenue growth (CAGR)
1.24%
3-year earnings per share growth (CAGR)
-22.55%
What the Analysts think about Personalis
Analyst ratings (Buy, Hold, Sell) for Personalis stock.
Analyst projections of the future price of Personalis stock.
Bulls say / Bears say
Clinical adoption is accelerating: second-quarter test volume rose 199% year on year to 10,384, while clinical revenue grew 442% and more than 1,400 physicians had ordered NeXT Personal. That gives the reimbursed diagnostics business a fast-growing base, albeit from a small starting point. (Personalis)
Medicare coverage now spans four NeXT Personal use cases, including lung cancer surveillance, immunotherapy monitoring and neoadjuvant breast cancer monitoring. Wider coverage could make more of the growing test volume reimbursable and support further clinical revenue growth. (Personalis)
New clinical findings presented at AACR support the assay’s potential beyond recurrence detection, including treatment-response monitoring and tracking resistance-related mutations. If these uses prove valuable in practice, they could help differentiate the platform and attract further clinical and pharma work. (Business Wire)
Personalis remains loss-making and cash-hungry: its May outlook called for a 2026 net loss of about $105 million and cash use of roughly $100 million. Rapid clinical growth will need to translate into much better margins before the business can fund itself. (Business Wire)
The proposed Tempus deal is not a fixed-cash exit: most consideration is in Tempus shares, and completion depends on approvals and other conditions. PSNL holders therefore face both transaction risk and exposure to Tempus’s share price before closing. (StockTitan, StockTitan)
Data summarised monthly by Lightyear AI. Last updated on 17 Oct 2026.
Personalis Financial Performance
Revenues and expenses
Personalis Earnings Performance
Company profitability
Upcoming events
No upcoming events
Personalis News
AllArticlesVideos
Personalis Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Personalis, Inc. - PSNL
Business Wire3 months ago
Tempus AI Makes Billion-Dollar Bet on the Future of Cancer Monitoring
Benzinga3 months ago
PSNL Stock Alert: Halper Sadeh LLC is Investigating Whether Personalis, Inc. is Obtaining a Fair Price for Shareholders
Business Wire3 months ago
Funds containing Personalis
AllUSDGBPEUR
Fund name | Fund size | $PSNL weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.11% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.11% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.04% |
SPDR Russell 2000 US Small Cap£R2SC | £4.1B | 0.04% |
iShares MSCI World Small Cap$WSML | $9B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.